Novo Nordisk’s phase 3 STEP Young trial found that 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo — a first efficacy readout for semaglutide in this young age group.
European Commission approves Wegovy 7.2 mg for obesity treatment. Clinical trial shows 21% average weight loss with 84% from fat mass. Now available across EU.
New data published in The New England Journal of Medicine shows the once-daily pill led to significant weight loss and improved cardiometabolic health in adults with obesity or who are overweight.
Novo Nordisk has unveiled compelling phase 3 data for its next-generation obesity drug, cagrilintide, at the EASD 2025 congress. The novel amylin analogue demonstrated a significant 11.8% average body weight reduction over 68 weeks, far surpassing the placebo group. These promising results have prompted the company to advance cagrilintide into a new dedicated clinical program, RENEW, set to begin later this year.
Semaglutide has transformed obesity and diabetes care, offering significant weight loss and glucose control with once-weekly dosing. Here’s a look at its clinical promise and expanding role in medicine.
Amgen presented Phase 2 data showing that its investigational obesity therapy, maritide, administered monthly, led to significant weight loss in adults with obesity or overweight. The treatment was generally well tolerated, supporting further clinical development.
